Creative Biolabs provides CRISPR/RNAi functional validation, quantifying gene silencing and knockout efficiency. We utilize high-throughput screening to evaluate signaling pathway disruption and validate novel therapeutic targets in oncology.
Learn More →Cancer Signaling Pathway Validation Services
Our service provides the functional evidence required to transition from a theoretical target to a validated therapeutic lead. We specialize in mapping the "signalome" to identify vulnerabilities that traditional screening methods often miss, such as feedback loops and metabolic bypasses. By partnering with Creative Biolabs, you receive a comprehensive biological roadmap that derisks your development process and provides the mechanistic data essential for regulatory submissions.
Background Featured Services Workflow Publication Why Choose Us FAQs Customer Review Related Services Contact Us
Service Overview: The Science of Signaling Validation
Modern oncology views signaling as a complex tripartite interaction between canonical pathways, metabolic sensing, and epigenetic plasticity. Research highlights that the vast majority of tumors harbor alterations in these pathways, yet resistance is often driven by molecular rewiring rather than simple mutation. Validation is the essential process of proving a specific node is a functional driver rather than a passenger. By correlating secondary messengers, we provide a holistic validation that ensures therapeutic efficacy within a heterogeneous microenvironment. Our approach synthesizes high-throughput data with mechanistic proof to identify vulnerabilities in the oncogenic signalome, providing the biological foundation necessary to advance candidate compounds from initial screening to successful therapeutic development.
Comprehensive Validation Portfolio for Oncogenic Signaling
Creative Biolabs offers an exhaustive suite of validation protocols designed to interrogate every facet of the oncogenic landscape. Our portfolio spans from canonical growth factor signaling to the emerging frontier of "oncometabolite" sensing and epigenetic remodeling.
CRISPR/RNAi Functional Validation
Inhibitor based Validation
Creative Biolabs provides inhibitor-based validation, quantifying signaling node suppression and IC50 potency. We utilize kinase inhibitors and small-molecule probes to evaluate pathway dependencies and bypass resistance in oncology research.
Learn More →Reporter Assay
Creative Biolabs provides reporter assays, quantifying luciferase and fluorescent signaling. We utilize stable cell lines to evaluate transcription factor activity and kinase inhibition for validating cancer-related signaling pathways.
Learn More →Phenotypic Validation
Creative Biolabs provides phenotypic validation, quantifying cell proliferation and signaling flux. We utilize high-resolution imaging and multi-omics to evaluate driver node necessity and bypass resistance in cancer pathways.
Learn More →Access Our Full Portfolio of Validation Modules – Contact Our Specialists for a Custom Proposal
Workflow
Our validation workflow is a meticulously structured, multi-stage pipeline designed to transform theoretical biological hypotheses into robust evidence for lead development.
Publication
This review examines mechanisms of tumor drug resistance, including clonal evolution, epigenetic modifications, cancer stem cell plasticity, and exosome-mediated signaling. It highlights how altered MAPK, PI3K/AKT, and JAK/STAT pathways drive resistance to targeted therapies and immunotherapies. The authors discuss single-cell analysis technologies for dissecting tumor heterogeneity and propose combination strategies targeting multiple pathways to overcome resistance, offering updated insights for improving cancer treatment efficacy.
Fig.1 An overview of MAPK, PI3K/AKT, and JAK signaling pathways and their interactions. 1
Why Choose Us?
Creative Biolabs stands at the forefront of oncology research with over two decades of specialized expertise. Our unique advantage lies in our ability to integrate metabolic sensing, epigenetic regulation, and immune signaling into a single validation pipeline. Unlike providers who offer fragmented data, we provide a systems-biology perspective supported by published data demonstrating that our validation strategies significantly improve the predictive power of pre-development models. We utilize specialized platforms to map feedback loops and bypass mechanisms that are the primary drivers of therapeutic escape.
Secure Your Development Roadmap – Access the Creative Biolabs Systems-Biology Advantage Now
FAQs
How do you handle cellular heterogeneity in your validation screens?
We utilize scRNA-seq and spatial transcriptomics to ensure that the signaling signatures we validate are specific to the tumor cells and not confounded by the surrounding stroma or fibroblasts.
Are your PDX and organoid models relevant for development?
We use patient-derived models that recapitulate the human tumor microenvironment far more accurately than traditional cell lines, providing higher translatability for your development programs.
Do you offer validation for combination therapies?
Absolutely. A core part of our service is identifying synergistic partners by mapping bypass pathways that are reactivated when your primary target is inhibited.
Customer Review
-
Superior Mechanistic Insights
Using Creative Biolabs' phospho-proteomic validation in our research has significantly facilitated our understanding of MAPK-bypass resistance. Their ability to map feedback loops in real-time was instrumental for our lead optimization. - Dr. A. Sm*th -
Reliable Metastatic Prediction
Implementing their signaling and immune infiltration analysis significantly facilitated our staging of T1/T2 gastric cancer leads. Their TIDE scoring was highly predictive of the results we later saw in PDX models. - Dr. L. M*er
Related Services
To further accelerate your oncology program, we recommend the following complementary services from Creative Biolabs:
Antibody & Protein Pharmacology Services
Creative Biolabs provides preclinical pharmacology profiling, quantifying TMDD and FcRn recycling. We utilize syngeneic, humanized, and organoid models to evaluate pharmacokinetics, dose predictions, and tumor suppression for immuno-oncology biologics.
Learn More →Immuno-Oncology Cell Assay Services
Creative Biolabs provides immuno-oncology cell-based assays, quantifying ADCC, CDC, ADCP, and T-cell cytotoxicity. We utilize flow cytometry and FluoroSpot to evaluate immune cell phenotyping, cytokine secretion, and activation markers.
Learn More →How to Contact Creative Biolabs
Creative Biolabs provides the scientific insight and technological infrastructure necessary to navigate the complexities of oncogenic signaling. From canonical pathway mapping to the latest in metabolic and epigenetic validation, we ensure your drug discovery process is both efficient and evidence-based.
For detailed information on our services or to discuss your specific project requirements with our senior scientists, please reach out via our inquiry portal.
Reference
- Li, Xiuzhi, et al. "Updates on altered signaling pathways in tumor drug resistance." Visualized Cancer Medicine 5 (2024): 6. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1051/vcm/2024007
Download our brochureLoading case studies...
Online Inquiry